Two contrasting insider signals dominated filings this week — a massive bet on a biotech and a wave of selling at a chip equipment giant.
SMMT saw its CEO and Chairman Robert Duggan file a $50M purchase on June 12. He bought 3.81 million shares at $13.12 each. That same week, President/CEO Maky Zanganeh filed a separate $1.46M buy. The CFO also added shares. Three executives buying at the same time is a strong vote of confidence from Summit Therapeutics' top team.
The picture at AMAT was the opposite. CEO Gary Dickerson filed sales totalling over $63M on June 17. The trades happened on June 15–16 at prices around $590–$597 per share. The company's CTO, Omkaram Nalamasu, filed another $9M in sales on the same dates. The board chairman sold nearly $5.6M more. Applied Materials insiders collectively offloaded well over $70M in just two days.
Also notable: DVA CEO Javier Rodriguez filed an $8.2M sale on June 17. He sold 39,407 shares in DaVita at roughly $209 each.
The SMMT cluster of buys stands out. When a CEO puts $50M of personal money into shares, that is rarely routine. The AMAT selling, by contrast, looks coordinated — multiple executives filing on the same day at similar prices.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
